Vaccine for deadly skin cancer shows ‘groundbreaking’ results in clinical trial
Fox News
New hope may be on the horizon for melanoma patients, as Moderna has announced promising results for its new skin cancer vaccine, which is now entering Phase III trials.
Among 157 patients with advanced melanoma, the vaccine led to "statistically significant improvement in survival before the cancer returned," according to a statement from Hackensack Meridian John Theurer Cancer Center in New Jersey, which has been participating in the clinical trials. In 2023, nearly 187,000 Americans were expected to be diagnosed with melanoma and more than 97,600 will die from the disease. Melissa Rudy is health editor and a member of the lifestyle team at Fox News Digital.
In the study, the vaccine was used in combination with Merck’s immunotherapy drug, Keytruda.